The ironman trial: A protocol for a multicentre randomized placebo-controlled trial of intravenous iron in intensive care unit patients with anaemia

Critical Care and Resuscitation

Volumn 16, Issue 4, 2014, Pages 285-290

  Litton, Edward ^a,b   Baker, Stuart ^c   Erber, Wendy ^d   French, Craig ^e,f   Ferrier, Janet ^a   Hawkins, David ^g   Higgins, Alisa M ^h   Hofmann, Axel ^i,j   De Keulenaer, Bart L ^d,k   Farmer, Shannon ^d,j   McMorrow, Julie ^a   Olynyk, John ^b   Richards, Toby ^d,l   Towler, Simon ^a   Webb, Steve ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e WESTERN HEALTH   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Department of Urology   (Australia)

^h MONASH UNIVERSITY   (Australia)

ⁱ Medical Society For Blood Management   (Austria)

^j CURTIN UNIVERSITY   (Australia)

^k FREMANTLE HOSPITAL   (Australia)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC CARBOXYMALTOSE; FERRIC ION; MALTOSE;

ANALOGS AND DERIVATIVES; ANEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANEMIA; CLINICAL PROTOCOLS; FERRIC COMPOUNDS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; MALTOSE; RESEARCH DESIGN;

EID: 84922274167     PISSN: 14412772     EISSN: 26529335     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. 1 Westbrook A, Pettilä V, Nichol A, et al; Blood Observational Study Investigators of ANZICS-Clinical Trials Group. Transfusion practice and guidelines in Australian and New Zealand intensive care units. Intensive Care Med 2010; 36: 1138-46
2. Vincent JL, Baron JF, Reinhart K, et al; ABC (Anemia and Blood Transfusion in Critical Care) Investigators. Anemia and blood transfusion in critically ill patients. JAMA 2002; 288: 1499-1507
3. Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study: anemia and blood transfusion in the critically ill — current clinical practice in the United States. Crit Care Med 2004; 32: 39-52
4. McQuilten ZK, Schembri N, Polizzotto MN, et al. Hospital blood bank information systems accurately reflect patient transfusion: results of a validation study. Transfusion 2011; 51: 943-8
5. Marik PE, Corwin HL. Efficacy of red blood cell transfusion in the critically ill: a systematic review of the literature. Crit Care Med 2008; 36: 2667-74
6. Shander A, Hofmann A, Gombotz H, et al. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007; 21: 271-89
7. Musallam KM, Tamim HM, Richards T, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011; 378: 1396-407
8. Hayden SJ, Albert TJ, Watkins TR, Swenson ER. Anemia in critical illness: insights into etiology, consequences, and management. Am J Respir Crit Care Med 2012; 185: 1049-57
9. Lasocki S, Longrois D, Montravers P, Beaumont C. Hepcidin and anemia of the critically ill patient: bench to bedside. Anesthesiology 2011; 114: 688-94
10. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347: f4822
11. Auerbach M, Coyne D, Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008; 83: 580-8
12. National Blood Authority Australia. Patient blood management guidelines. Module 4: critical care. Canberra: NBA, 2012. http:// www.nba.gov.au (accessed Sep 2014)
13. Fishbane S. Review of issues relating to iron and infection. Am J Kidney Dis 1999; 34 (4 Suppl 2): S47-52
14. Heming N, Lettéron P, Driss F, et al. Efficacy and toxicity of intravenous iron in a mouse model of critical care anemia. Crit Care Med 2012; 40: 2141-8
15. Pieracci FM, Stovall RT, Jaouen B, et al. A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness. Crit Care Med 2014; 42: 2048-57
16. Evstatiev R, Marteau P, Iqbal T, et al; FERGI Study Group. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011; 141: 846-53.e1-2
17. MIMS. Ferinject product information. Sydney: MIMS Australia & CMPMedica Australia. https://www.mimsonline.com.au (accessed Apr 2012)
18. Anker SD, Comin Colet J, Filippatos G, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-48
19. Coyne DW, Kapoian T, Suki W, et al; DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18: 975-84
20. Therapeutic Goods Administration. The Australian clinical trial handbook: a simple, practical guide to the conduct of clinical trials to International standards of Good Clinical Practice (GCP) in the Australian context. Version 1.1. Canberra: TGA, 2006
21. Cook D, Lauzier F, Rocha MG. Serious adverse events in academic critical care research. CMAJ 2008; 178: 1181-4.